Termination of Royalties Sample Clauses

Termination of Royalties. Royalties under Section 4.1, 4.2, or 4.4 will be due until the later of (i) ten years from the first commercial sale of Products in any country or (ii) on a country-by-country basis, the expiration of the last-to-expire patent within the Licensed Technology covering the Products in such country.
Sample 1Sample 2Sample 3See All (11)
AutoNDA by SimpleDocs
Termination of Royalties. The obligation. to pay royalties for Licensed Products payable under this Agreement shall be terminated for a patent in the event that the United States Patent and Trademark Office or a court of competent jurisdiction holds that a patent under the Licensed Patent Rights is invalid and/or unenforceable, in a decision from which no further rights of appeal are available, and when such event occurs no further royalties shall be due under that patent.
Sample 1Sample 2See All (4)
Termination of Royalties. The respective obligations on the part of CCI and the Manager to pay royalties pursuant to Sections 2(a) and 3(a) shall terminate immediately upon any dissolution of the Venture other than by virtue of its merger, amalgamation or consolidation with another corporation or entity or the sale of all or substantially all of its assets to another person or entity.
Sample 1Sample 2
Termination of Royalties. The royalty obligations set forth in Section 4.3 of the Sublicense Agreement, pursuant to which Inpharzam is to have made royalty payments to Sheffield, are hereby terminated. Any royalty obligations continuing between the parties from and after the date of this Amendment are set forth in Section 16 of this Amendment. The provisions of Sections 4.4, 4.5, 4.6, 4.7 and 4.8 are hereby amended so that they shall be deemed to apply only to the payment obligations of Sheffield to Inpharzam set forth in Section 16 of this Amendment.
Sample 1Sample 2
Termination of Royalties. Subject to the other provisions of this SCHEDULE 5, in the event of a Change in Control of Aironet (defined in Section 7.1 of this SCHEDULE 5), other than as a result of (i) a bona fide, firm commitment, underwritten, public offering of Aironet stock, or (ii) a spin-off, a dividend or any other distribution of Aironet stock by Telxon to its stockholders: 7.0.1 royalties shall be payable with respect to Aironet Technology Access Point software, Aironet Technology client software and any related chip set (i) until the date that is four (4) years after such event, (ii) until the date upon which total royalties of Four Million Dollars ($4,000,000) shall have been paid by Telxon following such event, or (iii) immediately if such Change in Control is in a transaction with a competitor of Telxon which derives twenty percent (20%) or more of its annual operating revenue from business(es) representing twenty percent (20%) or more of Telxon's annual operating revenues, whichever of clauses (i), (ii) or (iii) comes first, at which time all rights and licenses granted by Aironet to Telxon in this Agreement with respect to such software, and all royalties with respect to such software, shall be deemed to be fully paid up and no longer required to be paid; and 7.0.2 all rights and licenses granted by Aironet to Telxon in this Agreement with respect to all Aironet Technology other than the software and chip set described in Section 7.0.1 of this SCHEDULE 5, and all royalties with respect to all Aironet Technology other than the software and chip set described in Section 7.0.1 of this SCHEDULE 5 shall be deemed to be fully paid up and no longer required to be paid. 7.1 A "Change in Control" is deemed to have occurred if: 7.1.1 after the date hereof and prior to a bona fide, firm commitment, underwritten, initial public offering of Aironet stock, if any ("IPO"), (i) any Person other than the Investors (defined herein) becomes the "beneficial owner" (as defined in Rule 13d-3, as in effect on the date hereof, under the Securities Exchange Act of 1934 (as amended, the "Exchange Act")), directly or indirectly, of more than fifty percent (50%) of the combined voting power of Aironet's Voting Securities, or (ii) any Person other than the Investors becomes entitled to elect or designate a majority of the directors of Aironet's Board of Directors; 7.1.2 after an IPO, if (i) any Person becomes the beneficial owner, directly or indirectly, of twenty percent (20%) or more of the comb...
Sample 1
Termination of Royalties. Reference is made to that certain Assignment of Technology, dated March 2, 1992, between Employee and the Company as amended by that certain Addendum Agreement, executed as of December 2, 1996, between Employee and the Company (collectively, the “Assignment”). Employee agrees that the royalty provisions of the Assignment are hereby terminated, including all requirements that the Company pay any royalties to Employee for any technology assigned to the Company pursuant to the Assignment or for any new technologies developed by Employee and other improvements provided or anticipated to be provided by Employee, and including any provisions requiring reporting or information regarding technology assigned to the Company pursuant to the Assignment.
Sample 1
Termination of Royalties. Royalties payable under Section 3.2, offset as provided in Section 3.3 or reduced as provided in Section 3.5, and payments payable under Section 3.7, will be due on a Product-by-Product and country-by-country basis until the later of (i) ten (10) years from the first commercial sale of such Product in such country or (ii) the expiration of the last-to-expire patent containing a Valid Claim covering the Product in such country.
Sample 1
AutoNDA by SimpleDocs
Termination of Royalties. The obligation to pay royalties for Licensed Products payable under this Agreement shall be terminated for a patent in the event that the United States Patent and Trademark Office or a court of competent jurisdiction holds that a patent under the Licensed Patent Rights is invalid and/or unenforceable, in a decision from which no further rights of appeal are available, and when such event occurs no further royalties shall be due under that patent. The obligation to pay royalties for Licensed Products payable under this agreement shall also be terminated as to any specific Licensed Patent Right when that specific patent expires normally or due to non-payment of a maintenance fee or annuity to the appropriate Patent Office. Notice shall be provided by Licensor to Licensee of any events which affect Licensee's obligation to pay royalties.
Sample 1

Related to Termination of Royalties

  • Payment of Royalties To the best of Seller’s knowledge, all royalties and in-lieu royalties with respect to the Assets which accrued or are attributable to the period prior to the Effective Time have been properly and fully paid, or are included within the suspense amounts being conveyed to Buyer pursuant to Section 11.4.

  • Payment of Royalty The royalty obligation under Section 5.4 shall accrue upon the sales of a Licensed Product in each particular country in the Territory, commencing upon [***], and such obligation shall end upon the expiration of the Royalty Term applicable to such Licensed Product in such country. All such royalty payments are non-refundable and non-creditable and shall be due within [***] days of the end of each [***] and are payable in immediately available funds. ProNAi shall notify Marina in writing promptly upon the First Commercial Sale of Licensed Product in each country and thereafter ProNAi shall furnish Marina with a written report (the “Royalties Report”) for each completed [***] showing, on a country-by-country basis, according to the volume of units of Licensed Product sold in each such country (by SKU) during the reporting period (whether Licensed Product is sold by ProNAi or its Affiliates or Sublicensees): (a) the gross invoiced sales of the Licensed Product sold in each country during the reporting period, and the amounts deducted therefrom to determine Net Sales from such gross invoiced sales; (b) the royalties payable in dollars, if any, which shall have accrued hereunder based upon Net Revenues from sales of Licensed Product; and (c) the withholding taxes, if any, required by Applicable Law to be deducted in respect of such sales (provided that, as to sales by Sublicensees, ProNAi shall report only the net sales numbers (using the definition for such term in the applicable sublicense agreement) as reported by the Sublicensee, if such Sublicensee does not report gross invoiced sales numbers). With respect to sales of Licensed Product invoiced in US dollars, the gross invoiced sales, Net Revenues and royalties payable shall be expressed in the Royalties Report in US Dollars. With respect to sales of Licensed Product invoiced in a currency other than US dollars, the gross invoiced sales, Net Sales and royalties payable shall be expressed in the Royalties Report in the domestic currency of the party making the sale as well as in the US dollar equivalent of the Royalty payable and the exchange rate used in determining the amount of US dollars. The US dollar equivalent shall be calculated on a calendar-month basis using the average monthly interbank rate listed in the Wall Street Journal.

  • Earned Royalties In partial consideration of the License and subject to Sections 3.7 and 3.8, Company will pay to Penn: (i) a graduated royalty as set forth in the table below based upon worldwide annual Net Sales made by Company and its Affiliates (but not sublicensees) of any Designated Compound Sold for use in the Field of Use while covered in the country of Sale of expected use by a Valid Claim of the Assigned BMS Patents that is licensed to Company under the License (but no other Licensed Product): <$500 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$500 million but <$750 million [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$750 million but <$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% >$1 billion [CONFIDENTIAL TREATMENT REQUESTED] /*/% [CONFIDENTIAL TREATMENT REQUESTED] /*/ PATENT LICENSE AGREEMENT (ii) a royalty of [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%) of Net Sales made by Company and its Affiliates (but not sublicensees) for all Licensed Products that qualify as “Licensed Products” hereunder based on clause (b) of that definition and Sold while covered in the country of Sale of expected use by a Valid Claim of the Penn Existing Patents or Penn New Patents; provided that, notwithstanding any credits provided for in Section 3.7 but subject in all events to Section 3.8, royalties payable by Company for such Net Sales for such Licensed Products shall not be less than [CONFIDENTIAL TREATMENT REQUESTED] /*/ percent ([CONFIDENTIAL TREATMENT REQUESTED] /*/%). Only one royalty shall be due hereunder on the Sale of the same unit of Licensed Product. If a royalty accrues to a Sale of a Licensed Product under both clause (i) and (ii) above, then the higher rate of clause (i) shall apply. Only one royalty shall be due hereunder on the Sale of a Licensed Product even if the manufacture, use, sale, offer for sale or importation of such Licensed Product infringes more than one Valid Claim of the Penn Patent Rights.

  • Reports; Payment of Royalty During the Term following the First Commercial Sale of a Product, Merck shall furnish to Ambrx a quarterly written report for the Calendar Quarter showing the Net Sales of all Royalty Products subject to royalty payments sold by Merck and its Related Parties in the Territory for use in the Field during the reporting period and the royalties payable under this Agreement. Reports shall be due on the [***] day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. Merck shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined.

  • License of Data; Warranty; Termination of Rights A. The valuation information and evaluations being provided to the Trust by USBFS pursuant hereto (collectively, the “Data”) are being licensed, not sold, to the Trust. The Trust has a limited license to use the Data only for purposes necessary to valuing the Trust’s assets and reporting to regulatory bodies (the “License”). The Trust does not have any license nor right to use the Data for purposes beyond the intentions of this Agreement including, but not limited to, resale to other users or use to create any type of historical database. The License is non-transferable and not sub-licensable. The Trust’s right to use the Data cannot be passed to or shared with any other entity. The Trust acknowledges the proprietary rights that USBFS and its suppliers have in the Data. B. THE TRUST HEREBY ACCEPTS THE DATA AS IS, WHERE IS, WITH NO WARRANTIES, EXPRESS OR IMPLIED, AS TO MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OR ANY OTHER MATTER. C. USBFS may stop supplying some or all Data to the Trust if USBFS’s suppliers terminate any agreement to provide Data to USBFS. Also, USBFS may stop supplying some or all Data to the Trust if USBFS reasonably believes that the Trust is using the Data in violation of the License, or breaching its duties of confidentiality provided for hereunder, or if any of USBFS’s suppliers demand that the Data be withheld from the Trust. USBFS will provide notice to the Trust of any termination of provision of Data as soon as reasonably possible.

  • Termination of Rights The right of first refusal granted the --------------------- Company by Section 3(b) above and the option to repurchase the Shares in the event of an involuntary transfer granted the Company by Section 3(c) above shall terminate upon the first sale of Common Stock of the Company to the general public pursuant to a registration statement filed with and declared effective by the Securities and Exchange Commission under the Securities Act. Upon termination of the right of first refusal described in Section 3(b) and the expiration or exercise of the Repurchase Option, a new certificate or certificates representing the Shares not repurchased shall be issued, on request, without the legend referred to in Section 6(a)(ii) below and delivered to Purchaser.

  • Earned Royalty In addition to the annual license maintenance fee, ***** will pay Stanford earned royalties (Y%) on Net Sales as follows:

  • License Fees and Royalties Consistent with the applicable U.S. DOT Common Rules, the Recipient agrees that license fees and royalties for patents, patent applications, and inventions produced with federal assistance provided through the Underlying Agreement are program income, and must be used in compliance with federal applicable requirements.

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!